Core Insights - Nasus Pharma presented strong topline results from its Phase 2 clinical study of NS002, an intranasal epinephrine powder for treating anaphylaxis, demonstrating a significant advantage over EpiPen in time to therapeutic threshold [1][4]. Study Results - NS002 achieved effective epinephrine levels in a median of 1.69 minutes, compared to 3.42 minutes for EpiPen, with 67.4% of participants reaching therapeutic levels at 2.5 minutes versus 27.1% for EpiPen [2][18]. - The study showed NS002 consistently delivered faster and greater epinephrine exposure compared to intramuscular injection, while maintaining a comparable peak concentration and a favorable safety profile [3][16]. Clinical Performance - The Phase 2 study involved 50 healthy adults and evaluated NS002 under real-world conditions, including nasal congestion and repeat dosing scenarios, confirming its potential for practical use [14][15]. - NS002's pharmacokinetic profile demonstrated a T100 that is twice as fast as EpiPen, with 88.4% of subjects achieving the therapeutic threshold within 5 minutes compared to 64.6% for EpiPen [19][25]. Safety Profile - NS002 was well-tolerated with no serious adverse events reported, and most adverse events were mild and self-resolving, consistent with previous studies [16][23]. Future Plans - Based on the compelling results, Nasus Pharma plans to advance NS002 toward a pivotal study expected to initiate in the fourth quarter of 2026, highlighting its potential as a strategic asset for the company [4][27].